×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Showing results for
Lexicon
PHARMA
Search instead for
Lexicon PHARM
Lexicon Pharma (LXRX) Announces CEO Resignation
StreetInsider
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive...
2 weeks ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
Yahoo Finance
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript May 5, 2024 Lexicon Pharmaceuticals, Inc. isn't one of the 30...
1 week ago
Lexicon Pharma Stock: Significant Upside Tied To Successful Inpefa Commercialization
Seeking Alpha
Lexicon made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers.
3 months ago
Lexicon preps FDA resubmission for diabetes hopeful Zynquista
Fierce Pharma
Lexicon is hoping for an approval that clears the drug to be used as an add-on to insulin therapy for adults with Type 1 diabetes mellitus and...
2 months ago
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
GuruFocus
Revenue: Q1 2024 revenue was $1.1 million, primarily from net sales of Imperva.Net Income: Net loss for Q1 2024 was $48.4 million,...
1 week ago
Lexicon Pharma in financing agreement with Invus
Reuters
Lexicon Pharmaceuticals Inc. said on Sunday it entered into a financing agreement with investment firm The Invus Group LLC to help fund its...
5 months ago
Inpefa From Lexicon Pharmaceuticals, Inc.
Pharmacy Times
The FDA has approved sotaglifozin (Inpefa) oral tablets from Lexicon Pharmaceuticals, Inc, to reduce the risk of cardiovascular death,...
7 months ago
Diabetic Peripheral Neuropathy Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA ...
Barchart.com
The Diabetic Peripheral Neuropathy Market Forecast report offers an in-depth understanding of the Diabetic Peripheral Neuropathy,...
6 days ago
Lexicon Pharma (LXRX) Announces $250M Private Placement
StreetInsider
(Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private...
2 months ago
Lexicon poaches BMS' Tom Garner as new commercial lead to help with Inpefa launch
Fierce Pharma
Lexicon Pharmaceuticals spent years jumping and often falling over regulatory hurdles for its new heart drug Inpefa, but, after finally...
7 months ago